Revenue ($USD): $2,073,500,000
R&D spend: $92,000,000.00
Employees: 10,000
Fiscal year end: 12/31/22
CEO: Karim Bitar, CEO
Convatecannouncedin May that it partnered with Beta Bionics on the launch of the FDA-cleared iLet Bionic Pancreas for automated insulin delivery. The Beta Bionics iLet uses its inset and contact detach infusion sets for subcutaneous insulin administration.–SW and CN